首页> 外文期刊>Journal of neuro-oncology. >What is the translational efficacy of chemotherapeutic drug research in neuro-oncology? A systematic review and meta-analysis of the efficacy of BCNU and CCNU in animal models of glioma.
【24h】

What is the translational efficacy of chemotherapeutic drug research in neuro-oncology? A systematic review and meta-analysis of the efficacy of BCNU and CCNU in animal models of glioma.

机译:化疗药物研究在神经肿瘤学中的转化功效是什么?胶质瘤动物模型中BCNU和CCNU功效的系统评价和荟萃分析。

获取原文
获取原文并翻译 | 示例
       

摘要

Introduction The translational value of experimental therapeutic neuroscience research to clinical practice is highly variable. This has been particularly well demonstrated in the field of neuroprotective agents following either head injury or stroke. In this study we evaluate the efficacy of systemic BCNU and CCNU in experimental glioma models and how the experimental data has translated into clinical practice. Methods A systematic review of the efficacy of BCNU and CCNU, against experimental rodent and murine in vivo glioma models was conducted. Selected articles were graded on a 15 point scale for scientific methodology. A stratified meta-analysis based on median-survival data and effect sizes was performed to generate global-efficacy estimates for BCNU and CCNU, and to produce 'weighted-mean effect-sizes' for individual sub-categories of selected study-characteristics. Results Fourteen papers satisfied search criteria and encompassed 231 treatment comparisons in 2256 animals. The median methodologyscore was 9 (range 7-12/15). Global-efficacy estimates were BCNU 0.194 (95% CI -0.538 to 0.927) and CCNU 0.432 (95% CI -0.392 to 1.256), with CCNU being significantly more effective than BCNU. Because of these wide confidence intervals a beneficial or detrimental effect of either agent could not be confirmed. Most selected study-design characteristics (e.g. glioma cell line, drug dosage, drug scheduling, mode of drug administration, timing of therapy after glioma implantation but not animal used) significantly influenced the efficacy-results obtained. The methodological score did not influence efficacy-estimate. Conclusion This review has found (i) experimental-design influenced the efficacy-data obtained and (ii) that there is highly variable outcome data for the efficacy of both BCNU and CCNU in experimental in vivo rodent and murine glioma models. In many ways these findings are analagous to the use of nitrosoureas in human malignant glioma. The statistically significant small beneficial effect of nitrosoureas in combination with other chemotherapeutic agents in human glioma was only noted after a meta-analysis of human randomized controlled trials.
机译:引言实验性神经治疗科学研究对临床实践的转化价值具有很大的可变性。在头部受伤或中风后的神经保护剂领域,这一点已得到充分证明。在这项研究中,我们评估了全身性BCNU和CCNU在实验性神经胶质瘤模型中的功效以及实验数据如何转化为临床实践。方法对BCNU和CCNU对实验性啮齿动物和小鼠体内神经胶质瘤模型的疗效进行系统评价。所选文章的评分标准为15分,用于科学方法论。进行了基于中位生存数据和效应大小的分层荟萃分析,以生成BCNU和CCNU的全局功效估计值,并为选定研究特征的各个子类别生成“加权平均效应大小”。结果有14篇论文符合检索标准,包括2256只动物的231种治疗比较。中位方法学得分为9(范围7-12 / 15)。全球效能评估为BCNU 0.194(95%CI -0.538至0.927)和CCNU 0.432(95%CI -0.392至1.256),其中CCNU比BCNU更有效。由于这些较大的置信区间,因此无法确认任何一种试剂的有益或有害作用。大多数选定的研究设计特征(例如神经胶质瘤细胞系,药物剂量,药物时间表,药物施用方式,神经胶质瘤植入后但未使用动物的治疗时间)显着影响所获得的疗效结果。方法学评分不影响疗效评估。结论本综述发现(i)实验设计影响了所获得的功效数据,并且(ii)在实验性啮齿动物和鼠神经胶质瘤模型中BCNU和CCNU功效的结果数据差异很大。这些发现在许多方面都与亚硝基脲在人类恶性神经胶质瘤中的使用相似。仅在对人类随机对照试验进行荟萃分析后,才注意到亚硝基脲与其他化学治疗剂联合治疗人脑胶质瘤的统计学显着的小获益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号